Epstein-Barr virus (EBV) DNA detection in whole blood at time of post-transplant lymphoproliferative disorder (PTLD) diagnosis in solid organ transplant patients

2016 ◽  
Author(s):  
Carlos Cervera
Keyword(s):  
Whole Blood ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Barr Virus ◽  
Transplant Patients ◽  
Ebv Dna ◽  
Epstein Barr

scholarly journals Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)

Blood ◽  
2006 ◽  
Vol 108 (9) ◽  
pp. 2942-2949 ◽  
Author(s):  
Barbara Savoldo ◽  
John A. Goss ◽  
Markus M. Hammer ◽  
Lan Zhang ◽  
Teresita Lopez ◽  
...  
Keyword(s):  
High Risk ◽  
T Lymphocytes ◽  
Cytotoxic T Lymphocytes ◽  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

AbstractWe have investigated the in vivo safety, efficacy, and persistence of autologous Epstein Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) for the treatment of solid organ transplant (SOT) recipients at high risk for EBV-associated posttransplantation lymphoproliferative disease (PTLD). EBV-CTLs generated from 35 patients expanded with normal kinetics contained both CD8 and CD4 lymphocytes and produced significant specific killing of autologous EBV-transformed B lymphoblastoid cell lines (LCLs). Twelve SOT recipients at high risk for PTLD, or with active disease, received autologous CTL infusions without toxicity. Real-time polymerase chain reaction (PCR) monitoring of EBV-DNA showed a transient increase in plasma EBV-DNA suggestive of lysis of EBV-infected cells, although there was no consistent decrease in virus load in peripheral-blood mononuclear cells. Interferon-γ enzyme-linked immunospot (ELISPOT) assay and tetramer analysis showed an increase in the frequency of EBV-responsive T cells, which returned to preinfusion levels after 2 to 6 months. None of the treated patients developed PTLD. One patient with liver PTLD showed a complete response, and one with ocular disease has had a partial response stable for over one year. These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity.

B-cell lymphoproliferative disorders in solid-organ transplant patients: Detection of Epstein-Barr virus by in situ hybridization

1992 ◽  
Vol 23 (2) ◽  
pp. 159-163 ◽  
Author(s):  
Laurence C. Berg ◽  
Cedith M. Copenhaver ◽  
Vicki A. Morrison ◽  
Scott A. Gruber ◽  
David L. Dunn ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Lymphoproliferative Disorders ◽  
Solid Organ ◽  
Barr Virus ◽  
Transplant Patients ◽  
Epstein Barr

scholarly journals High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders

2000 ◽  
Vol 38 (2) ◽  
pp. 613-619 ◽  
Author(s):  
Fausto Baldanti ◽  
Paolo Grossi ◽  
Milena Furione ◽  
Lavinia Simoncini ◽  
Antonella Sarasini ◽  
...  
Keyword(s):  
Predictive Value ◽  
Epstein Barr Virus ◽  
Immunosuppressive Treatment ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

Epstein-Barr virus (EBV) DNA was quantitated in peripheral blood mononuclear cells (PBMC) from 25 healthy subjects, 105 asymptomatic solid-organ transplant (SOT) recipients, and 15 SOT recipients with symptomatic EBV infections by using a newly developed quantitative-PCR technique. Patients with symptomatic EBV infections had significantly higher (P < 0.001) median EBV DNA levels than asymptomatic SOT recipients and immunocompetent individuals. In SOT recipients, the positive predictive value of EBV DNA levels of >1,000 genome equivalents (GE)/0.5 μg of total PBMC DNA was 64.7% for symptomatic EBV infection, while the negative predictive value was 96.1%. In 19 of 32 (59.3%) asymptomatic SOT recipients, EBV DNA levels were consistently below 1,000 GE for as long as 18 months, while 10 of 32 (31.2%) patients had 1,000 to 5,000 EBV GE at least once during follow-up. In a minority of patients (3 of 32; 9.3%), ≥5,000 GE could be detected at least once during follow-up. Reduction of immunosuppressive treatment decreased EBV DNA levels by ≥1 log10 unit in patients with symptomatic EBV infections. Quantification of EBV DNA is valuable for the diagnosis and monitoring of symptomatic EBV infections in SOT recipients.

scholarly journals Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus

2000 ◽  
Vol 38 (2) ◽  
pp. 712-715 ◽  
Author(s):  
Hubert G. M. Niesters ◽  
Joost van Esser ◽  
Edwin Fries ◽  
Katja C. Wolthers ◽  
Jan Cornelissen ◽  
...  
Keyword(s):  
Real Time ◽  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ ◽  
Plasma Samples ◽  
Serum Samples ◽  
Barr Virus ◽  
Transplant Patients ◽  
Ebv Dna ◽  
Epstein Barr

With the use of real-time PCR, we developed and evaluated a rapid, sensitive, specific, and reproducible method for the detection of Epstein-Barr virus (EBV) DNA in plasma samples. This method allowed us to screen plasma and serum samples over a range between 100 and 107 copies of DNA per ml using two sample preparation methods based on absorption. A precision study yielded an average coefficient of variation for both methods of less than 12%, with a coefficient of regression for the standard curve of a minimum of 0.98. We detected EBV DNA in 19.2% of plasma samples from immunosuppressed solid-organ transplant patients without symptoms of EBV infections with a mean load of 440 copies per ml. EBV DNA could be detected in all transplant patients diagnosed with posttransplant lymphoproliferative disorder, with a mean load of 544,570 copies per ml. No EBV DNA could be detected in healthy individuals in nonimmunosuppressed control groups and a mean of 6,400 copies per ml could be detected in patients with infectious mononucleosis. Further studies revealed that the inhibitory effect of heparinized plasma could be efficiently removed by use of an extraction method with Celite as the absorbent.

Cell specific internal translation efficiency of Epstein–Barr virus present in solid organ transplant patients

2007 ◽  
Vol 79 (5) ◽  
pp. 573-581 ◽  
Author(s):  
Åsa Isaksson ◽  
Malin Berggren ◽  
Kerstin Ekeland-Sjöberg ◽  
Tore Samuelsson ◽  
Anne Ricksten
Keyword(s):  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Translation Efficiency ◽  
Barr Virus ◽  
Transplant Patients ◽  
Epstein Barr ◽  
Internal Translation

scholarly journals Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders

1999 ◽  
Vol 37 (4) ◽  
pp. 1113-1116 ◽  
Author(s):  
Ajit P. Limaye ◽  
Meei-Li Huang ◽  
Ederlyn E. Atienza ◽  
James M. Ferrenberg ◽  
Lawrence Corey
Keyword(s):  
Epstein Barr Virus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Barr Virus ◽  
Ebv Dna ◽  
Solid Organ Transplant Recipients ◽  
Epstein Barr

Early diagnosis of Epstein-Barr Virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) is important because many patients respond to reduction in immunosuppression, especially if PTLD is detected at an early stage. Previous studies have found elevated EBV DNA levels in blood from patients with PTLD, but these assays required isolation of cellular blood fractions and quantitation. We evaluated the presence of cell-free EBV DNA in serum from solid-organ transplant recipients as a marker for PTLD. Five of 6 transplant recipients with histopathologically documented PTLD had EBV DNA detected in serum at the time of diagnosis (sensitivity = 83%), compared with 0 of 16 matched transplant recipients without PTLD (specificity = 100%) (P < 0.001 [Fisher’s exact test]). Furthermore, EBV DNA was detected in serum 8 and 52 months prior to the diagnosis of PTLD in two of three patients for whom stored sera were analyzed. Detection of EBV DNA in serum appears to be a useful marker for the early detection of PTLD in solid-organ transplant recipients. Further studies to define the role of such assays in evaluating solid-organ transplant patients at risk for PTLD are warranted.

Sign in / Sign up

Export Citation Format

Share Document